Selective PDE2 Inhibition for Ventricular Tachycardia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological treatments for ventricular tachycardia, such as beta-blockers and Class 1 anti-arrhythmics, are often ineffective and have significant side-effects, while existing PDE2 inhibitors are not specifically indicated for cardiac arrhythmias, let alone ventricular tachycardia, and prior suggestions on PDE2 activation may even exacerbate arrhythmias.
Innovation Solution
The use of selective PDE2 inhibitors to activate the Na+/K+-ATPase (NKA) and regulate cAMP levels locally, providing a novel treatment strategy for ventricular tachycardia with reduced side-effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-arrhythmic drugs (beta-blockers, Class 1C agents) are used to treat ventricular tachycardia, then heart rhythm control is attempted, but adverse side-effects occur frequently and treatment must be discontinued in about 20% of patients
Solution Approach 1:
The patent changes the pharmacological parameter from conventional beta-blockers and Class 1C anti-arrhythmics to selective PDE2 inhibitors, fundamentally altering the mechanism of action while maintaining therapeutic effectiveness against ventricular tachycardia
Solution Approach 2:
The patent extracts and isolates the specific PDE2 enzyme target from the general phosphodiesterase family, developing selective inhibitors that act specifically on PDE2 without significantly affecting other PDE isoforms, thereby reducing off-target side effects
2Adaptability or versatility
If existing PDE2 inhibitors are used, then cognitive function may be improved, but they are not specifically indicated for cardiac arrhythmias and may even exacerbate arrhythmias through PDE2 activation
Solution Approach 1:
The patent inverts the previously suggested mechanism by demonstrating that PDE2 inhibition (not activation) is therapeutic for ventricular tachycardia, reversing the earlier hypothesis about PDE2's role in arrhythmia pathogenesis
Solution Approach 2:
The patent establishes that selective PDE2 inhibitors can serve multiple functions: treating cognitive disorders and simultaneously providing cardioprotection against ventricular tachycardia, expanding the therapeutic utility of this enzyme target
3Reliability
If PDE2 activity is increased (activation), then cognitive function may be enhanced, but ventricular tachyarrhythmias are exacerbated
Solution Approach 1:
The patent inverts the previously suggested mechanism by demonstrating that PDE2 inhibition (not activation) is therapeutic for ventricular tachycardia, reversing the earlier hypothesis about PDE2's role in arrhythmia pathogenesis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PDE2 inhibition effectively prevents ventricular tachyarrhythmias by increasing NKA activity, reducing intracellular Ca2+ loading, and offering a safer alternative to conventional drugs with fewer adverse reactions.
Implementation Method 1
PDE2 is one of a number of different phosphodiesterases (PDEs) found in mammals. The PDE family of enzymes regulates intracellular levels of the secondary messenger cyclic nucleotides cAMP and/or cGMP through hydrolytic control.
Implementation Method 2
We propose herein the local and selective activation of Na +
Data Source
Figure 1A~1C
Figure 2A~2D
Figure 3A~3C
AI summary
The invention provides compounds which are selective PDE2 inhibitors for use in the treatment of tachycardia or tachyarrhythmia. Such compounds are particularly suitable for use in the treatment of any of the following conditions: atrial tachycardia, atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, premature ventricular contractions (PVCs), ventricular fibrillation and ventricular tachycardia, and may be used alone or in combination therapy with other conventional cardiovascular drugs, e.g. beta-blockers. In particular, the invention provides compounds which are selective PDE2 inhibitors for use in the treatment of ventricular tachycardia in patients who are suffering from, or who are at risk of suffering from heart failure, CPVT or long QT syndrome.